Prognostic Significance of the Systemic Immune-Inflammation Index (SII) in Patients With Small Cell Lung Cancer: A Meta-Analysis

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Feb 21

PMID 35186750

Authors

Yuting Zhou

Menglu Dai

Zongxin Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Previous studies have investigated the prognostic value of the systemic immune-inflammation index (SII) in small cell lung cancer (SCLC). However, the results have been inconsistent. The study aimed to investigate the prognostic and clinicopathological significance of SII in SCLC through a meta-analysis.

Methods: The PubMed, Web of Science, Embase, Cochrane Library, and China National Knowledge Infrastructure databases were thoroughly searched. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to evaluate the prognostic value of the SII for survival outcomes. The combined odds ratios (ORs) and 95% CIs were used to evaluate the correlation between SII and clinicopathological features.

Results: Eight studies comprising 2,267 patients were included in the meta-analysis. Pooled analyses indicated that a high SII was significantly associated with worse overall survival (OS) (HR=1.52, 95% CI=1.15-2.00, p=0.003) but not progression-free survival (HR=1.38, 95% CI=0.81-2.35, p=0.238) in patients with SCLC. Moreover, a high SII was associated with extensive-stage SCLC (OR=2.43, 95% CI=1.86-3.17, p<0.001). However, there was a non-significant correlation between SII and age, sex, smoking history, Karnofsky Performance Status score, or initial therapeutic response.

Conclusion: Our meta-analysis demonstrated that a high SII could be an efficient prognostic indicator of OS in SCLC. We recommend adopting SII to predict OS in patients with SCLC, and SII in combination with other parameters or biomarkers may aid in addressing the clinical strategy and choosing the best treatment for an individual patient.

Citing Articles

Impact of systemic immune-inflammation index and its evaluation of optimal threshold in patients with limited-stage small cell lung cancer: a retrospective study based on 572 cases.

Zhang Z, Zhao Y, Wen J, Wang Y, Li J Transl Cancer Res. 2025; 14(1):371-382.

PMID: 39974395 PMC: 11833402. DOI: 10.21037/tcr-24-1266.

Prognostic value of systemic immune-inflammation index in patients with small-cell lung cancer treated with immune checkpoint inhibitors.

Hamakawa Y, Hirahara A, Hayashi A, Ito K, Shinohara H, Shiba A BMC Cancer. 2025; 25(1):17.

PMID: 39762819 PMC: 11706134. DOI: 10.1186/s12885-025-13440-5.

Systemic immune-inflammatory index predict short-term outcome in recurrent/metastatic and locally advanced cervical cancer patients treated with PD-1 inhibitor.

Chen Q, Zhai B, Li J, Wang H, Liu Z, Shi R Sci Rep. 2024; 14(1):31528.

PMID: 39732889 PMC: 11682050. DOI: 10.1038/s41598-024-82976-6.

The association between systemic immune-inflammation index (SII) and early nosocomial infections after cardiopulmonary bypass surgery in children with congenital heart disease.

Li M, Nie Y, Yang Z BMC Cardiovasc Disord. 2024; 24(1):698.

PMID: 39633275 PMC: 11619183. DOI: 10.1186/s12872-024-04378-w.

Pretreatment systemic immune-inflammation index and lymphocyte-to-monocyte ratio as prognostic factors in oral cavity cancer: A meta-analysis.

Xu J, Lin Y, Yang J, Xing Y, Xing X Medicine (Baltimore). 2024; 103(44):e40182.

PMID: 39496022 PMC: 11537607. DOI: 10.1097/MD.0000000000040182.

References

Liu S, Reck M, Mansfield A, Mok T, Scherpereel A, Reinmuth N . Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol. 2021; 39(6):619-630. PMC: 8078320. DOI: 10.1200/JCO.20.01055. View

Yilmaz A, Tekin S, Bilici M, Yilmaz H . The Significance of Controlling Nutritional Status (CONUT) Score as a Novel Prognostic Parameter in Small Cell Lung Cancer. Lung. 2020; 198(4):695-704. DOI: 10.1007/s00408-020-00361-2. View

Yao J, Shao Y, Wang J, Li Y, Yang H, Liu J . Evaluation of diagnostic and predictive values of the serum VEGF-A level and systemic immune-inflammation index in small cell lung cancer. J Cancer. 2021; 12(5):1356-1364. PMC: 7847641. DOI: 10.7150/jca.51972. View

De Giorgi U, Procopio G, Giannarelli D, Sabbatini R, Bearz A, Buti S . Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab. Clin Cancer Res. 2019; 25(13):3839-3846. DOI: 10.1158/1078-0432.CCR-18-3661. View

Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A . Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006; 24(28):4539-44. DOI: 10.1200/JCO.2005.04.4859. View

Bambace N, Holmes C . The platelet contribution to cancer progression. J Thromb Haemost. 2010; 9(2):237-49. DOI: 10.1111/j.1538-7836.2010.04131.x. View

Remon J, Aldea M, Besse B, Planchard D, Reck M, Giaccone G . Small cell lung cancer: a slightly less orphan disease after immunotherapy. Ann Oncol. 2021; 32(6):698-709. DOI: 10.1016/j.annonc.2021.02.025. View

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

Wang Q, Zhu D . The prognostic value of systemic immune-inflammation index (SII) in patients after radical operation for carcinoma of stomach in gastric cancer. J Gastrointest Oncol. 2019; 10(5):965-978. PMC: 6776812. DOI: 10.21037/jgo.2019.05.03. View

10.

Man Y, Stojadinovic A, Mason J, Avital I, Bilchik A, Bruecher B . Tumor-infiltrating immune cells promoting tumor invasion and metastasis: existing theories. J Cancer. 2013; 4(1):84-95. PMC: 3564249. DOI: 10.7150/jca.5482. View

11.

Criscitiello C, Esposito A, Trapani D, Curigliano G . Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer. Cancer Treat Rev. 2016; 50:205-207. DOI: 10.1016/j.ctrv.2016.09.019. View

12.

Katayama S, Mori K, Pradere B, Laukhtina E, Schuettfort V, Quhal F . Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer. World J Urol. 2021; 39(12):4355-4361. PMC: 8602174. DOI: 10.1007/s00345-021-03740-3. View

13.

Cui X, Jia Z, Chen D, Xu C, Yang P . The prognostic value of the C-reactive protein to albumin ratio in cancer: An updated meta-analysis. Medicine (Baltimore). 2020; 99(14):e19165. PMC: 7220550. DOI: 10.1097/MD.0000000000019165. View

14.

Murthy P, Zenati M, Al Abbas A, Rieser C, Bahary N, Lotze M . Prognostic Value of the Systemic Immune-Inflammation Index (SII) After Neoadjuvant Therapy for Patients with Resected Pancreatic Cancer. Ann Surg Oncol. 2019; 27(3):898-906. PMC: 7879583. DOI: 10.1245/s10434-019-08094-0. View

15.

Qi W, Xiang Y, Zhao S, Chen J . Assessment of systematic inflammatory and nutritional indexes in extensive-stage small-cell lung cancer treated with first-line chemotherapy and atezolizumab. Cancer Immunol Immunother. 2021; 70(11):3199-3206. PMC: 10991671. DOI: 10.1007/s00262-021-02926-3. View

16.

Hu B, Yang X, Xu Y, Sun Y, Sun C, Guo W . Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014; 20(23):6212-22. DOI: 10.1158/1078-0432.CCR-14-0442. View

17.

Chen L, Kong X, Wang Z, Wang X, Fang Y, Wang J . Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy. J Cell Mol Med. 2020; 24(5):2993-3021. PMC: 7077539. DOI: 10.1111/jcmm.14934. View

18.

Dvorak H . Tumor Stroma, Tumor Blood Vessels, and Antiangiogenesis Therapy. Cancer J. 2015; 21(4):237-43. DOI: 10.1097/PPO.0000000000000124. View

19.

Hong X, Cui B, Wang M, Yang Z, Wang L, Xu Q . Systemic Immune-inflammation Index, Based on Platelet Counts and Neutrophil-Lymphocyte Ratio, Is Useful for Predicting Prognosis in Small Cell Lung Cancer. Tohoku J Exp Med. 2015; 236(4):297-304. DOI: 10.1620/tjem.236.297. View

20.

Berardi R, Santoni M, Rinaldi S, Bower M, Tiberi M, Morgese F . Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer. Ann Transl Med. 2019; 7(20):572. PMC: 6861803. DOI: 10.21037/atm.2019.09.18. View